Streetwise Reports Interviews Executives at Biotech Company

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
67
Streetwise Reports Interviews Executives at Biotech Company with Transformative RNAi Delivery System

SAN FRANCISCO, CA --(Marketwired - October 05, 2017) - With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.

Included in this interview is: RXi Pharmaceuticals Corp. ( NASDAQ : RXII )

The Life Sciences Report: How far has RXi Pharmaceuticals Corp. come in the last 10 years?

Geert Cauwenbergh: Since the codiscovery of RNAi by Dr. Craig Mello, the field has had to overcome many development hurdles. In the beginning, the main issue was efficient delivery of RNAi compounds to tissues and cells. RXi took the time to examine the delivery aspect and developed a technology platform where delivery and therapeutic properties are built directly into the compound. This development is a major breakthrough in the field and we have broadly protected the intellectual property (IP) around it, which laid the foundation for development as a company.

We began operations about five years ago and the company decided to explore a skin indication as the first clinical development program, because you can see and feel skin. We initiated a clinical program in dermatology with our lead compound, RXI-109.

Continue reading this article: Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

RXi Pharmaceuticals Corp. is a billboard sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclaimers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. The discussion does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer .

Please see the end of the interview for the complete disclosures: Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End

Contact Information: Carrie Beal Amaro Associate Publisher Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 150

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 176

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 161

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 191

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 261

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategic Alliance Between Vireo and Curio Enhances Growth Opportunities

Updated Category News Views 201

Strategic Partnership Announced Leading cannabis companies Vireo Growth Inc. and Curio Wellness have forged a partnership aimed at leveraging shared resources to tap into the burgeoning cannabis market. This collaboration marks an exciting new chapter for both companies as they work to introduce innovative health and wellness products to consumers. Vireo Growth Inc.: A...

Continue Reading
G42 and Mistral AI Collaborate for Innovative AI Solutions

Updated Category News Views 251

Strategic Partnership between G42 and Mistral AI In a significant development for global artificial intelligence, G42, a technology group based in Abu Dhabi, has teamed up with Mistral AI, a reputable AI company headquartered in Paris. This partnership was announced during the Choose France event and stands as a testament to the collaborative spirit between the UAE and...

Continue Reading
Trellus Marketplace Launches: A New Era for Local Shopping

Updated Category News Views 303

Launch of Trellus Marketplace Revolutionizes Local Shopping Trellus Marketplace has made a significant entrance into the e-commerce world, becoming the first platform entirely dedicated to the unique offerings of Long Island's small businesses. This innovative online marketplace allows consumers to shop for local goods directly from their desktops, iOS, and Android...

Continue Reading
Gunderson Dettmer Expands Leadership with New Chief Revenue Officer

Updated Category News Views 275

Gunderson Dettmer Welcomes Erin Stone Dimry Gunderson Dettmer is thrilled to announce the appointment of Erin Stone Dimry as the Chief Revenue Officer. As a global leader in the innovation economy, the firm recognizes the importance of strategic leadership for its continued growth and success. Significance of Erin's Role In her new position, Erin will collaborate closely...

Continue Reading
Newly Approved Services by AB Ignitis Gamyba Benefit Consumers

Updated Category News Views 203

Introduction to the New Regulations AB “Ignitis grup?” has announced a significant development regarding the services provided by its subsidiary, AB “Ignitis gamyba.” The National Energy Regulatory Council (NERC) has recently approved a resolution aimed at amending previous regulations pertaining to the methodology for calculating electricity prices and other...

Continue Reading